To manage manufacturing sites bought from UCB
In anticipation of its acquisition of three manufacturing sites from UCB, Aesica Pharmaceuticals has appointed a team to direct and manage its new European operation.
The UK-based contract pharmaceutical services provider anticipates that the deal will be completed in the first quarter.
The three manufacturing sites are located in Monheim and Zwickau in Germany and Pianezza in Italy.
Simon Clough, who has been with Aesica for over three years, will become managing director, Formulated Products Business Unit, and will be based at the Monheim site. Katy Lineker will support him as finance director, Formulated Products Business Unit.
Aesica has also appointed three ambassadors to support the transition following the completion of the deal. Janette Waterhouse will be based at Zwickau for three months, Edd Wood will spend three months at Pianezza and Helen Taylor will relocate to Monheim for three months.
They will be responsible for ensuring that the full expertise and capability of the staff is used, maintaining current high standards of production, while establishing a platform from which new business can be developed across all three sites.
Robert Hardy, chief executive of Aesica, said: ‘Simon has been instrumental in making this acquisition and our entry into the European manufacturing market a reality and I am delighted that he will be directing and implementing our vision across the three sites with the support of Katy and our ambassadors.’